US2022378932A1PendingUtilityA1
Fusion proteins for delivery of gdnf to the cns
Est. expiryOct 7, 2025(expired)· nominal 20-yr term from priority
A61P 25/28A61K 38/185A61K 47/6811A61K 2039/505C07K 16/2869C07K 2319/00C07K 16/2881C07K 2317/24C07K 2319/01A61K 47/6849C07K 2319/30C07K 14/475
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.
Claims
exact text as granted — not AI-modified1 .- 28 . (canceled)
29 . A composition comprising alpha-L-iduronidase (IDUA) covalently linked to the amino terminus of an antigen binding fragment of an antibody or to an antibody fragment binding to a transferrin receptor that is capable of crossing the blood brain barrier (BBB), wherein the composition is capable of producing an average elevation of concentration in the brain of the IDUA of at least about 1 ng/gram brain following intravenous administration, and wherein the composition comprises a mineral acid salt or a salt of an organic acid.Join the waitlist — get patent alerts
Track US2022378932A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.